All In Biotech

Drug Trial Radar · NCT00829829

PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1

A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Rilonacept for the Prophylaxis of Gout Flares During the Initiation of Allopurinol Therapy

Last checked: Nov 20, 2026Latest source record: Apr 28, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 241 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

241

Actual

Start

Feb 2009

Primary completion

May 2010

Study completion Jun 2010

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Jan 27, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical research study was to determine the safety and effectiveness of an experimental drug called rilonacept in subjects with gout who are beginning allopurinol treatment for gout. Subjects will participate in this study for approximately 22 weeks. Rilonacept is being studied for use in preventing allopurinol-induced gout flares.

Conditions

  • Intercritical Gout

Interventions

  • PlaceboOther

    Placebo loading dose followed by placebo injections (2 mL) qw for 16 weeks.

  • Rilonacept 80 mgDrug

    Rilonacept 160 mg loading dose followed by Rilonacept 80 mg/2 mL injections qw for 16 weeks.

  • Rilonacept 160 mgDrug

    Rilonacept 320 mg loading dose followed by Rilonacept 160 mg/2 mL injections qw for 16 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Gout Flares Per Participant Assessed From Day 1 to Day 112 (Week 16)Time frame: Day 1 to Day 112 (Week 16)

Locations

91 sites in 2 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Gilbert, Arizona

  • Site not named

    Peoria, Arizona

  • Site not named

    Searcy, Arkansas

  • Site not named

    Concord, California

  • Site not named

    San Diego, California

  • Site not named

    Santa Maria, California

  • Site not named

    Trumball, Connecticut

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Daytona Beach, Florida

  • Site not named

    Delray Beach, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Jupiter, Florida

  • Site not named

    Naples, Florida

  • Site not named

    St. Petersburg, Florida

  • Site not named

    Gainsville, Georgia

  • Site not named

    Rome, Georgia

  • Site not named

    Tucker, Georgia

  • Site not named

    Woodstock, Georgia

  • Site not named

    Boise, Idaho

  • Site not named

    Avon, Indiana

  • Site not named

    Evansville, Indiana

  • Site not named

    South Bend, Indiana

  • Site not named

    Wichita, Kansas

  • Site not named

    Bowling Green, Kentucky

  • Site not named

    Owensboro, Kentucky

  • Site not named

    Baltimore, Maryland

  • Site not named

    Ellicott City, Maryland

  • Site not named

    Resistertown, Maryland

  • Site not named

    Troy, Michigan

  • Site not named

    Jackson, Mississippi

  • Site not named

    Florissant, Missouri

  • Site not named

    Las Vegas, Nevada

  • Site not named

    Las Vegas, Nevada

  • Site not named

    Berkeley Heights, New Jersey

  • Site not named

    Freehold, New Jersey

  • Site not named

    Brooklyn, New York

  • Site not named

    Greensboro, North Carolina

  • Site not named

    Hickory, North Carolina

  • Site not named

    Morehead City, North Carolina

Showing 40 of 91 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.